Elicio Therapeutics (ELTX) Accounts Payables (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Accounts Payables came in at $272000.0 in Q1 2026, down 93.26% YoY from $4.0 million in Q1 2025, and down 59.52% on a QoQ basis from $672000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Accounts Payables (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Accounts Payables data on file, last reported at $272000.0 in Q1 2026.
- Quarterly Accounts Payables fell 93.26% year-over-year to $272000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $272000.0 (down 93.26% YoY) and the FY2025 annual result came in at $672000.0, down 35.26% from the prior year.
- Accounts Payables declined to $272000.0 in Q1 2026, from $672000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $4.4 million in Q3 2023 to a low of $272000.0 in Q1 2026.
- A 5-year average of $2.3 million and a median of $2.2 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2025 — Accounts Payables jumped 266.35% — and 2026, when it slumped 93.26%.
- Tracing ELTX's Accounts Payables over 5 years: stood at $2.8 million in 2022, then jumped by 55.76% to $4.4 million in 2023, then plunged by 76.24% to $1.0 million in 2024, then tumbled by 35.26% to $672000.0 in 2025, then tumbled by 59.52% to $272000.0 in 2026.
- The last three Accounts Payables figures came in at $272000.0 (Q1 2026), $672000.0 (Q4 2025), and $321000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 839,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 839,000.00 |
| Mar 31, 2026 | 272,000.00 |
| Dec 31, 2025 | 672,000.00 |
| Sep 30, 2025 | 321,000.00 |
| Jun 30, 2025 | 3.87 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 4.37 Mn |
| Sep 30, 2023 | 4.41 Mn |
| Jun 30, 2023 | 4.27 Mn |
| Mar 31, 2023 | 692,000.00 |
| Dec 31, 2022 | 2.81 Mn |
| Sep 30, 2022 | 2.22 Mn |
| Jun 30, 2022 | 2.66 Mn |
| Mar 31, 2022 | 3.43 Mn |
| Dec 31, 2021 | 4.71 Mn |
| Sep 30, 2021 | 7.68 Mn |